Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.

Victoza and Saxenda use another GLP-1 agonist, liraglutide. Tirzepatide — Eli Lilly’s branded versions are sold as Mounjaro for blood sugar and Zepbound for weight loss — works on two hormones.

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.